**NM signifies a non meaningful value. A dash signifies the data is not available.

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Though the drugmaker had performed well since the beginning of the decade, it encountered issues that ...

The figure also surpassed the Zacks Consensus Estimate of $44.96. Regeneron initiated a quarterly cash dividend program and declared a dividend of $0.88 per share. The dividend is payable on March ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first starting to issue payouts. Given the strength of its underlying operations ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...